HeartCon左心室辅助装置治疗20例成人终末期心力衰竭的短期疗效
该前瞻性观察研究纳入2020年9月至2021年8月在泰达国际心血管病医院心脏外科植入HeartCon左心室辅助装置的20例终末期心力衰竭患者(男15例、女5例,平均年龄50.2±13.6岁)。比较术前与术后90天的左心室舒张末期内径、左室射血分数、NYHA分级、N末端B型利钠肽原和6分钟步行距离,并记录90天内器械故障与主要不良事件。结果显示左心室舒张末期内径显著下降、左室射血分数显著升高、N末端B型利钠肽原显著下降、6分钟步行距离显著增加(均P<0.05),18例(90%)NYHA分级达I级、2例(10%)达II级。作者认为HeartCon左心室辅助装置可有效改善终末期心衰患者生活质量,临床试验已证实安全有效,但长期效果与并发症需进一步观察研究。
要点
- 20例终末期心衰患者植入HeartCon左心室辅助装置,手术全部成功,住院时间33~90天,平均56.0(42.8,75.0)天。
- 术后90天左室射血分数从术前22.70%±5.62%升至34.80%±9.76%,左心室舒张末期内径从77.40±9.73 mm降至67.50±13.98 mm(均P<0.05)。
- 术后90天N末端B型利钠肽原从4796.45±4355.40 ng/L降至2028.65±1752.05 ng/L,6分钟步行距离从85.81±63.50 m增至385.20±144.12 m(均P<0.05)。
- 术后90天NYHA分级:18例(90%)达I级、2例(10%)达II级;术前全部患者为IV级。
- 90天内无器械机械故障、溶血、右心衰、脑梗死和死亡;出血与感染并发症包括消化道出血5例(25%)、心包填塞2例(10%)、脑出血1例(5%)、纵隔感染1例(5%)、急性肾损伤3例(15%)。
适用人群与场景
- 2020年9月至2021年8月在泰达国际心血管病医院心脏外科接受HeartCon左心室辅助装置植入的终末期心力衰竭成人患者,年龄20~67岁,体重49.8~106.1 kg,体表面积1.49~2.32 m²。
研究设计与关键结果
- 前瞻性观察研究,纳入20例终末期心衰患者(男15例、女5例),平均年龄50.2±13.6岁,平均体重67.9±15.5 kg,平均体表面积(原文如此)17.6±0.22 m²;手术全部成功。
- 术后90天较术前:左室射血分数34.80%±9.76% vs. 22.70%±5.62%,左心室舒张末期内径67.50±13.98 mm vs. 77.40±9.73 mm,N末端B型利钠肽原2028.65±1752.05 ng/L vs. 4796.45±4355.40 ng/L,6分钟步行距离385.20±144.12 m vs. 85.81±63.50 m,差异均有统计学意义(均P<0.05)。
- 术后90天NYHA分级I级18例(90%)、II级2例(10%),术前全部患者为IV级。
- 90天内并发症:心包填塞2例(10%)、脑出血1例(5%)、纵隔感染1例(5%)、急性肾损伤3例(15%)、消化道出血5例(25%)。
- 90天内无左心室辅助装置机械故障、溶血事件、右心衰、脑梗死和死亡。
证据类型、等级与局限
- 证据类型:前瞻性观察研究;局限:原文报告长期效果与并发症需进一步观察研究。
对床旁实践的改变
- 作者认为HeartCon左心室辅助装置可有效改善终末期心衰患者的生活质量,临床试验已证实其安全有效,但长期效果与并发症需进一步观察研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate and evaluate the efficacy of HeartCon left ventricular assist device (LVAD) in the treatment of adult patients with end-stage heart failure (ESHF).
METHODS: A prospective and observational study was conducted. Patients with ESHF who underwent LVAD implantation in the department of cardiac surgery of Teda International Cardiovascular Hospital from September 2020 to August 2021 were selected. The left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) classification, N-terminal pro-B type natriuretic peptide (NT-proBNP), and six minute walk distance (6MWD) before operation and 90 days after operation were compared. The incidence of equipment failures and major adverse events within 90 days after operation were recorded.
RESULTS: A total of 20 patients with ESHF were included, with 15 males and 5 females. Patients' age ranged from 20 to 67 years old, with an average of (50.2±13.6) years old. The range of body weight was 49.8-106.1 kg, with an average of (67.9±15.5) kg, and the body surface area (BSA) was from 1.49 to 2.32 m2, with an average of (17.6±0.22) m2. The operation process of all the patients were successful. The length of hospital stay ranged from 33 to 90 days, and the average was 56.0 (42.8, 75.0) days. Complications within 90 days after operation as follows, 2 cases with pericardial tamponade (10%), 1 case with cerebral hemorrhage (5%), 1 case with mediastinum infection (5%), 3 cases with acute renal injury (AKI, 15%), 5 cases with gastrointestinal bleeding (25%). There were no mechanical failure of LVAD and hemolysis events, right ventricular failure (RVF), cerebral infarction and death occurred. Compared with preoperative, the LVEDD significantly decreased (mm: 67.50±13.98 vs. 77.40±9.73), LVEF significantly increased (%: 34.80±9.76 vs. 22.70±5.62), NT-proBNP significantly decreased (ng/L: 2 028.65±1 752.05 vs. 4 796.45±4 355.40), 6MWD significantly increased (m: 385.20±144.12 vs. 85.81±63.50) at 90 days after operation, and the differences were statistically significant (all P < 0.05). 18 cases (90%) of the 20 patients reached NYHA classification I and 2 cases (10%) reached NYHA classification II, which were significantly improved compared with those before surgery (all patients' NYHA classification were IV before surgery).
CONCLUSIONS: HeartCon LVAD can effectively improve the life quality of patients with ESHF, which has been proved safe and effective in clinical trials, but its long-term effects and complications need further observation and study.
参考来源
- Wang W, Song Y, Zhang Y, et al. [Short-term effect of HeartCon left ventricular assist device on the treatment of 20 adult patients with end-stage heart failure]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36567579. doi:10.3760/cma.j.cn121430-20220106-00015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。